NO802497L - Fremgangsmaate for fremstilling av et veterinaerpreparat - Google Patents

Fremgangsmaate for fremstilling av et veterinaerpreparat

Info

Publication number: NO802497L
Authority: NO; Norway
Prior art keywords: preparation; group; stated; compound; animals
Prior art date: 1979-08-23

Application number

NO802497A

Other languages

English (en)

Norwegian (no)

Inventor

Peter Martin Newsome

Noel Austin Mullen

Original Assignee

Beecham Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-08-23

Filing date

1980-08-22

Publication date

1981-02-24

1980-08-22 Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd

1981-02-24 Publication of NO802497L publication Critical patent/NO802497L/no

Links

238000002360 preparation method Methods 0.000 title claims description 29
238000000034 method Methods 0.000 title claims description 13
150000001875 compounds Chemical class 0.000 claims description 49
241001465754 Metazoa Species 0.000 claims description 42
206010012735 Diarrhoea Diseases 0.000 claims description 21
230000000694 effects Effects 0.000 claims description 11
239000005526 vasoconstrictor agent Substances 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
239000003651 drinking water Substances 0.000 claims description 7
235000020188 drinking water Nutrition 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 6
239000000695 adrenergic alpha-agonist Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
239000008215 water for injection Substances 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000002619 bicyclic group Chemical group 0.000 claims description 2
239000006071 cream Substances 0.000 claims description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
239000000446 fuel Substances 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000002243 precursor Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
238000005303 weighing Methods 0.000 claims 1
241000588724 Escherichia coli Species 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 6
239000000147 enterotoxin Substances 0.000 description 6
231100000655 enterotoxin Toxicity 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000369 enteropathogenic effect Effects 0.000 description 5
RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 5
229960005045 lidamidine Drugs 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
241000282887 Suidae Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000001142 anti-diarrhea Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
229960004760 naphazoline hydrochloride Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
101710146739 Enterotoxin Proteins 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
206010022998 Irritability Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CNIIGCLFLJGOGP-UHFFFAOYSA-N SJ000285664 Natural products C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
239000003874 central nervous system depressant Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000002011 intestinal secretion Anatomy 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
244000144972 livestock Species 0.000 description 2
229960005016 naphazoline Drugs 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
229960000337 tetryzoline Drugs 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229960002925 clonidine hydrochloride Drugs 0.000 description 1
229940078069 clonidine injection Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000003022 colostrum Anatomy 0.000 description 1
235000021277 colostrum Nutrition 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229940090044 injection Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
-1 methoxy, hydroxy Chemical group 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
239000000133 nasal decongestant Substances 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229960000833 xylometazoline Drugs 0.000 description 1
229960001095 xylometazoline hydrochloride Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NO802497A 1979-08-23 1980-08-22 Fremgangsmaate for fremstilling av et veterinaerpreparat NO802497L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7929434		1979-08-23

Publications (1)

Publication Number	Publication Date
NO802497L true NO802497L (no)	1981-02-24

Family

ID=10507398

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO802497A NO802497L (no)	1979-08-23	1980-08-22	Fremgangsmaate for fremstilling av et veterinaerpreparat

Country Status (14)

Country	Link
US (2)	US4332814A (el)
EP (2)	EP0086428B1 (el)
JP (1)	JPS5634628A (el)
AU (1)	AU533436B2 (el)
CA (1)	CA1156147A (el)
DE (1)	DE3071229D1 (el)
DK (1)	DK363180A (el)
ES (1)	ES494433A0 (el)
GR (1)	GR69871B (el)
IE (1)	IE51143B1 (el)
IL (1)	IL60809A0 (el)
NO (1)	NO802497L (el)
NZ (1)	NZ194591A (el)
ZA (1)	ZA804795B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0086428B1 (en) *	1979-08-23	1987-07-29	Beecham Group Plc	Antidiarrhoea veterinary composition, its production and oral doser containing it
DE3168754D1 (en) *	1980-07-09	1985-03-21	Beecham Group Plc	Clonidine derivatives useful in the treatment of diarrhoea
DE3360148D1 (en) *	1982-02-10	1985-06-05	Beecham Group Plc	Guanidine derivatives
GB8313588D0 (en) *	1983-05-17	1983-06-22	Beecham Group Plc	Compounds
US4714707A (en) *	1984-01-13	1987-12-22	Rorer Pharmaceutical Corporation	Aryl substituted heterocycles for treating gastrointestinal motility dysfunction
DE3428342A1 (de) *	1984-08-01	1986-02-13	Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim	Futtermittelzusatz zur verbesserung des wachstums bei landwirtschaftlichen nutztieren
US5171575A (en) *	1987-01-19	1992-12-15	Nisshin Flour Milling Co., Ltd.	Process for preventing diarrhea in animals
CA1321751C (en) *	1989-02-21	1993-08-31	Eugene C. Crichlow	Mechanism mediating ruminal stasis in ruminal lactic acidosis
US5352691A (en) *	1993-02-16	1994-10-04	Thomas Peter G	Effective treatment modality for adult respiratory distress syndrome using L-histidine
NZ333370A (en) *	1993-12-17	2001-03-30	Procter & Gamble	6-(2-Imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) *	1993-12-17	1996-11-19	The Procter & Gamble Company	7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
CA2179006A1 (en) *	1993-12-17	1995-06-22	Peter Julian Maurer	6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) *	1993-12-17	1996-11-26	The Procter & Gamble Company	6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) *	1993-12-17	1995-12-26	The Procter & Gamble Company	5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5869458A (en) *	1994-10-14	1999-02-09	Waite; Christopher S.	Frozen rehydration formulation and delivery system therefor
PL323496A1 (en) *	1995-05-23	1998-03-30	Smithkline Beecham Plc	Pharmaceutic composition obtained by adding a taste improving agent to a drug
US5916900A (en)	1995-06-29	1999-06-29	The Procter & Gamble Company	7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5741807A (en) *	1996-09-27	1998-04-21	Cytos Pharmaceuticals, L.P.	Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
EP1037887B1 (en)	1997-11-24	2004-07-14	The Procter & Gamble Company	5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US20040071793A1 (en) *	2002-10-05	2004-04-15	Bobrowski Paul J.	Oral rehydration methods and compositions
US20050136105A1 (en) *	2003-12-22	2005-06-23	Allen Marni L.	Consumer customized dosage forms
US7371405B2 (en) *	2003-12-22	2008-05-13	Mcneil-Ppc, Inc.	Consumer customized dosage forms
TW200806282A (en) *	2006-05-05	2008-02-01	Wyeth Corp	Solid dosage formulations
KR200466495Y1 (ko) *	2010-12-14	2013-04-23	황연지	좌변기용 어린이 다리 받침장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2731471A (en) *		1956-01-17		Nxg hi
US2842478A (en) *	1955-08-25	1958-07-08	Pfizer & Co C	Tetrahydrozoline-central nervous system depressant veterinary compositions and method of using same
FR1217629A (fr) *	1956-07-10	1960-05-04	Ciba Geigy	Procédé de préparation de la 2-(p-tertio-butyl-o,o'-diméthyl-phényl-méthyl)-imidazoline et de ses sels
US2915431A (en) *	1956-07-17	1959-12-01	Lab Robert & Carriere Sa Des	2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses
DE1154119B (de) *	1961-11-30	1963-09-12	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
BE754935A (fr) *	1969-08-13	1971-02-17	Hoechst Ag	2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
SE7407022L (el) *	1973-06-06	1974-12-09	Wander Ag Dr A
NZ183492A (en) *	1976-03-27	1980-04-28	Beecham Group Ltd	Veterinary rehydration compositions containing monosaccharide amino acid and citric acid or citrate
CA1072962A (en)	1976-08-11	1980-03-04	George H. Douglas	Process for preparing amidinoureas
US4122190A (en) *	1976-10-04	1978-10-24	Sandoz Ltd.	Treating acromegaly
EP0086428B1 (en) *	1979-08-23	1987-07-29	Beecham Group Plc	Antidiarrhoea veterinary composition, its production and oral doser containing it
US4312879A (en) *	1980-08-14	1982-01-26	Richardson-Merrell Inc.	Clonidine and lofexidine as antidiarrheal agents

1980
- 1980-08-04 EP EP83101136A patent/EP0086428B1/en not_active Expired
- 1980-08-04 DE DE8080302647T patent/DE3071229D1/de not_active Expired
- 1980-08-04 EP EP80302647A patent/EP0025269B1/en not_active Expired
- 1980-08-07 NZ NZ194591A patent/NZ194591A/xx unknown
- 1980-08-08 IL IL60809A patent/IL60809A0/xx unknown
- 1980-08-11 US US06/177,365 patent/US4332814A/en not_active Expired - Lifetime
- 1980-08-17 ZA ZA00804795A patent/ZA804795B/xx unknown
- 1980-08-19 CA CA000358579A patent/CA1156147A/en not_active Expired
- 1980-08-21 GR GR62714A patent/GR69871B/el unknown
- 1980-08-21 AU AU61631/80A patent/AU533436B2/en not_active Ceased
- 1980-08-22 IE IE1776/80A patent/IE51143B1/en unknown
- 1980-08-22 ES ES494433A patent/ES494433A0/es active Granted
- 1980-08-22 NO NO802497A patent/NO802497L/no unknown
- 1980-08-22 JP JP11578080A patent/JPS5634628A/ja active Pending
- 1980-08-22 DK DK363180A patent/DK363180A/da not_active Application Discontinuation
1982
- 1982-02-19 US US06/350,403 patent/US4520014A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JPS5634628A (en)	1981-04-06
IL60809A0 (en)	1980-10-26
IE801776L (en)	1981-02-23
AU533436B2 (en)	1983-11-24
EP0086428B1 (en)	1987-07-29
DK363180A (da)	1981-02-24
EP0086428A1 (en)	1983-08-24
US4520014A (en)	1985-05-28
ES8106486A1 (es)	1981-07-01
US4332814A (en)	1982-06-01
AU6163180A (en)	1981-04-09
EP0025269B1 (en)	1985-11-13
ES494433A0 (es)	1981-07-01
ZA804795B (en)	1981-07-29
EP0025269A1 (en)	1981-03-18
NZ194591A (en)	1983-06-17
CA1156147A (en)	1983-11-01
DE3071229D1 (en)	1985-12-19
GR69871B (el)	1982-07-20
IE51143B1 (en)	1986-10-15

Publication	Publication Date	Title
NO802497L (no)	1981-02-24	Fremgangsmaate for fremstilling av et veterinaerpreparat
Wolff et al.	1983	Efficacy of triclabendazole against Fasciola hepatica in sheep and goats
DE69428350T2 (de)	2002-06-13	Polymere ionene als anthelminthika in tieren
CN101987100B (zh)	2012-07-25	一种硫酸头孢喹肟混悬注射液的制备方法
RU2527347C1 (ru)	2014-08-27	Стабильная жидкая фармацевтическая композиция комплекса 3-(2,2,2-триметилгидразиний) пропионат-2-этил-6-метил-3-гидроксипиридина дисукцината, обладающая антигипоксическим, антиоксидантным и адаптогенным действием
CN101953871B (zh)	2012-05-23	一种动物用抗菌药物及其制备方法和应用
WO2007140588A1 (en)	2007-12-13	Pathogenic attenuation via the administration of an equilibiotic compound
EP0059057A1 (en)	1982-09-01	Treatment of diarrhoea
CN103417477B (zh)	2015-08-05	一种以水为基质的多拉菌素o/w型注射液及其制备方法
EP0112061A2 (en)	1984-06-27	Pharmaceutical or veterinary compositions containing guanoxabenz
CN1985827B (zh)	2012-11-07	兽用复方环丙沙星注射液及其制备工艺
AU2021102382A4 (en)	2021-06-24	Method of Controlling Parasites
Cox et al.	1989	Effect of antisecretory drugs on experimentally induced weanling diarrhoea in piglets
RU2203651C2 (ru)	2003-05-10	Способ лечения и профилактики желудочно-кишечных, легочных стронгилятозов и цестодозов овец
CN103083337A (zh)	2013-05-08	兽用增效磺胺甲氧哒嗪注射液的制备方法
CN103083336A (zh)	2013-05-08	兽用增效磺胺甲氧哒嗪注射液
NZ204129A (en)	1985-11-08	Treating infective keratoconjunctivitis in animals using cloxacillin salt
US3592894A (en)	1971-07-13	Treatment of intestinal helminthiasis with tetrachlorofulvenes
RU1751890C (ru)	1995-09-20	Препарат для лечения колибактериоза телят "ромиксин"
CN104784182B (zh)	2017-07-21	一种治疗畜禽腹泻的组合物及其制备方法
KR20220041862A (ko)	2022-04-01	크립토스포리듐증의 예방 및/또는 치료를 위한 수의학적 조성물
DISGUST	2008	LINDA A. PARKER, CHERYL L. LIMEBEER, AND SHADNA A. RANA
KUTTLER et al.	2012	11. Chemotherapy of babesiosis
CN102973578A (zh)	2013-03-20	一种防治禽支原体和大肠杆菌混合感染的复方制剂及制备工艺
INJECTABLE	0	An Ideal Sultonamide for Veterinary Medicine